title: Pap test--with or without vaginal smear?
abstract: The aim of this study was to evaluate medical and economic justification of vaginal smears as a part of primary screening for cervical carcinoma and its precursors. Study included 245.048 participants whose VCE (vaginal, cervical, endocervical) smears were examined at Department of clinical cytology of University Hospital Center Osijek from 2003 till 2008. There were 12.639 (5.2%) abnormal findings, and they were divided into three groups: abnormal cells found only in vaginal smear (V), abnormal cells found in vaginal and in at least one other smear (V+) and abnormal cells not found in vaginal smear (C/E). These three groups were analysed in respect to cytological differential diagnosis and age of participants. It was estimated how many women could be additionally included in the screening, if vaginal smear would be included in the Pap test only after 50 years of age. In 6.9% of cytologically diagnosed lesions abnormal cells were found exclusively in vaginal smears (0.35% of all findings). As for squamous cell lesions, 91.2% were mild lesions (ASC and LSIL). Invasive squamous cell carcinoma was not diagnosed exclusively by vaginal smear in either woman under 50 years of age, while in women over 50 years of age it was diagnosed in 2.3% of cases. Exclusively by vaginal smear was diagnosed 3.9% of all AGC and 6.3% of adenocarcinoma, while in 85.0% of glandular epithelium lesions abnormal cells were not found in vaginal smears. Two thirds of adenocarcinoma diagnosed exclusively by vaginal smears were endometrial adenocarcinoma, but that is only 10.3% of all endometrial carcinoma diagnosed by Pap test. Obtained results show that taking of vaginal smears along with cervical and endocervical smears as a part of primary screening for cervical carcinoma and its precursors in women under 50 years of age is not justifiable, since vaginal smear only has a role in detection of endometrial carcinoma that are extremely rare in younger age groups. If vaginal smear would be taken only in women over 50 years of age, additional 37.7% of women under 50, or 25.1% women over 50 years of age could be included in the screening.
authors.affiliation: Department of Clinical Cytology, University Hospital Center Osijek, Osijek, Croatia. valerija.mj@gmail.com
authors.forename: Valerija
authors.initials: V
authors.lastname: Milicić-Juhas
authors.forename: Marija
authors.initials: M
authors.lastname: Perić
authors.forename: Marija
authors.initials: M
authors.lastname: Pajtler
authors.forename: Ivana
authors.initials: I
authors.lastname: Prvulović
authors.forename: Darko
authors.initials: D
authors.lastname: Curzik
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology*; D000367:Age Factors; D018269:Carcinoma, Endometrioid / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000473:pathology*; D005260:Female; D017048:Health Care Costs; D006801:Humans; D008403:Mass Screening / Q000191:economics / Q000379:methods*; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000473:pathology; D002583:Uterine Cervical Neoplasms / Q000473:pathology*; D014626:Vaginal Smears / Q000191:economics / Q000379:methods*